Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3499446 in KRAS G12C Mutated Advanced Solid Tumors
NCT04165031Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of LY3499446 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Overall Response Rate and 1 more. Started Nov 2019; status: terminated.
02
Drugs
LY3499446
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04165031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165031.